Checked 2026-11-10. Independent clinical review has not been completed. WADAFUK is independent of WADA and does not provide medical advice or an individual anti-doping determination.
Prohibited at all times
Oxandrolone is covered by S1.1 of the effective 2026 WADA List and is prohibited in and out of competition. S1.1 applies to exogenous administration; its coverage is not limited to the named examples and includes relevant esters. [4]
S1.1; 2026 List, printed pages 5–6 · 2026 rules apply from 1 January 2026. Any 2027 material below concerns future rules from 1 January 2027; it is not current clearance.
US regulatory history
FDA’s October 2026 correction confirms that Oxandrin and the referenced generic applications were withdrawn for reasons of safety or effectiveness. Most named approvals were withdrawn in June 2023; the Roxane application had been withdrawn in 2009. Old labels must not be presented as current US approval. [2]
- This determination is US-specific; it does not establish availability in every country.
Human evidence
A single-center randomized trial enrolled 222 children with severe burns and compared oxandrolone with placebo, with a further exercise allocation. It reported improvements in recovery-related measures including growth, bone mineral content and strength. [1]
- Abstract-only appraisal. Findings in severe pediatric burns are not evidence of benefit or safety in healthy athletes and do not reverse subsequent FDA action.
List year
The 2026 List is the effective edition on this review date. The checked 2027 S1 text showed no change, but the 2027 edition does not take effect until 1 January 2027. [4] [5] [3]
- Consult the official edition and responsible anti-doping organization for consequential decisions. This reference does not provide medical advice, a TUE decision, product certification or individual clearance.
What remains uncertain
- This is a targeted source check, not a systematic review or independent clinical/regulatory sign-off. Uncited draft claims remain unpublished.
- Chemical registry identifiers, every alias and jurisdiction-specific product availability have not been exhaustively reconciled.
Check the sources.
These are concise editorial paraphrases of selected sources, not a systematic review or a reproduction of source tables. Access depth is shown for each reference; an abstract-only check cannot resolve details found only in a full paper.
- Five-year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial of safety and efficacy. ↗Accessed 2026-11-10 · indexed original abstract read via Europe PMC MED record; full article not reviewed
Abstract; PMID 22463890
- Determination That Oxandrin Tablets Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction ↗Accessed 2026-11-10 · relevant primary-source text read
Summary and corrections 1–3; 91 FR 64154–64155
- 2027 Prohibited List resource page ↗Accessed 2026-11-10 · relevant primary-source text read · FUTURE 2027 SOURCE
Resource description and effective date
- WADA 2026 Prohibited List ↗Accessed 2026-11-10 · relevant primary-source text read
Introduction and S1, printed pages 3, 5–6
- WADA 2027 Prohibited List, currently linked English file ↗Accessed 2026-11-10 · relevant primary-source text read · FUTURE 2027 SOURCE
Cover and S1, printed pages 1, 5–6
Check the current official WADA List and the relevant anti-doping authority for your sport, product, route and circumstances. Do not stop or change necessary treatment based on this page. Ask a qualified clinician about health decisions. Missing evidence does not establish safety.